Background: Posttraumatic stress disorder (PTSD) is a severe and frequent affection that is highly comorbid to major depressive disorder. Comorbid PTSD and depression increase the risk of treatment-resistant depression (TRD), with a high risk of functional impairment and suicide. Esketamine nasal spray is a recent validated treatment for TRD, but its efficacy on comorbid TRD-PTSD remains...
Current models of post-traumatic stress disorder (PTSD) predominantly focus on emotional dysregulation, avoidance behaviors, and intrusive symptoms, with limited attention to disturbances in bodily self-consciousness. These frameworks do not fully account for how trauma may disrupt the integration of interoceptive and exteroceptive signals underlying the sense of embodied self. Building on...
Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted...